LON:REDX Redx Pharma (REDX) Share Price, News & Analysis → I’m officially sounding the alarm. (From Altimetry) (Ad) Free REDX Stock Alerts GBX 11.57 -1.18 (-9.25%) (As of 02:27 PM ET) Add Compare Share Share Today's Range 11.50▼ 12.7050-Day Range 4.25▼ 2252-Week Range 4▼ 37.90Volume72,039 shsAverage Volume696,042 shsMarket Capitalization£45.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get Redx Pharma alerts: Email Address Ad AltimetryI’m officially sounding the alarm.AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.Just click here to watch my full uncensored interview. About Redx Pharma Stock (LON:REDX)Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers. In addition, it is developing RXC009, a potent and selective DDR1 inhibitor, which is in preclinical studies for the treatment of chronic kidney disease; Kirsten rat sarcoma virus (KRAS) inhibitor to target G12D selective and multi-KRAS profiles; RXC006/AZD5055 a porcupine inhibitor, which is in Phase 1 clinical trial for targeting fibrotic diseases, including idiopathic pulmonary fibrosis; JZP815, a pan-rapidly accelerated fibrosarcoma inhibitor that is in Phase 1 clinical trial to overcome resistance mechanisms associated with clinically approved B-RAF selective drugs; and mitogen-activated protein kinase pathway targets for oncology indications. The company has research collaboration agreements with Jazz Pharmaceuticals plc to develop JZP815, as well as discovery and preclinical development of a targeted cancer therapy on the Ras/RAF/MAP kinase pathway; and AstraZeneca plc to develop RXC006/AZD5055, a Porcupine inhibitor for the treatment of fibrotic disease. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.Read More REDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REDX Stock News HeadlinesApril 19, 2024 | insidertrades.comRedx Pharma Plc (LON:REDX) Insider Lisa Anson Buys 115,000 SharesApril 13, 2024 | insidertrades.comInsider Buying: Redx Pharma Plc (LON:REDX) Insider Acquires 399,000 Shares of StockApril 19, 2024 | InvestorPlace (Ad)New crypto project uncovers 2,050% in 65 daysDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.April 18, 2024 | americanbankingnews.comRedx Pharma Plc (LON:REDX) Insider Purchases £10,350 in StockApril 13, 2024 | morningstar.comRedx Pharma PLC REDXApril 13, 2024 | thetimes.co.ukExodus from Aim leaves chorus of questions in its wakeApril 12, 2024 | americanbankingnews.comRedx Pharma Plc (LON:REDX) Insider Acquires £31,920 in StockApril 10, 2024 | msn.comLondon markets are broken and closed, says pharma bossApril 19, 2024 | InvestorPlace (Ad)New crypto project uncovers 2,050% in 65 daysDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.April 10, 2024 | msn.comIs the London Stock Exchange’s AIM in terminal decline?April 7, 2024 | ft.comThe Lex Newsletter: The UK has a two-speed market problemApril 3, 2024 | ft.comDo not blame London for this latest stock market departureApril 2, 2024 | thetimes.co.ukRedX Pharma blames finance constraints for quitting stock marketApril 2, 2024 | msn.comPharma Redx is latest firm to delist from AIMApril 2, 2024 | uk.investing.comSterling ticks up as UK manufacturing recoversApril 2, 2024 | lse.co.ukAIM WINNERS & LOSERS: 88 Energy finds oil at Hickory-1; Redx to delistApril 2, 2024 | msn.comLondon loses another listed company as pharma riser goes privateApril 2, 2024 | msn.comFTSE 100 Live 2 April: Blue-chips in surprise jump to top 8000, near record high; house prices dip in MarchApril 2, 2024 | lse.co.ukRedx Pharma plummets on plans to delist from AIMMarch 8, 2024 | finance.yahoo.comRedx Pharma achieves milestone with dosing of first participant in Phase 1 clinical trial for RXC008February 14, 2024 | marketwatch.comRedx Pharma Says Not Involved in U.S.-Listing ProcessFebruary 14, 2024 | msn.comRedx Pharma denies US listing plan following reportFebruary 13, 2024 | morningstar.comRedx Pharma PLC 0RXFebruary 8, 2024 | finance.yahoo.comJAZZ Boosts Oncology Pipeline With KRAS Inhibitor ProgramFebruary 8, 2024 | finance.yahoo.comRedx Pharma lands biggest deal to date with sale of KRAS inhibitor programme to Jazz PharmaFebruary 7, 2024 | thetimes.co.ukRedx Pharma seals $880m cancer research partnershipFebruary 7, 2024 | lse.co.ukRedx Pharma Share ChatSee More Headlines Receive REDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Redx Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/19/2018Today4/19/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:REDX CUSIPN/A CIKN/A Webredxpharma.com Phone+44-151-7064747FaxN/AEmployees101Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-33,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-180.80% Return on Assets-43.95% Debt Debt-to-Equity Ratio527.00 Current Ratio1.11 Quick Ratio1.93 Sales & Book Value Annual Sales£4.20 million Price / Sales11.14 Cash FlowGBX 2.30 per share Price / Cash Flow5.23 Book ValueGBX 1 per share Price / Book12.03Miscellaneous Outstanding Shares388,990,000Free FloatN/AMarket Cap£46.80 million OptionableNot Optionable Beta-0.53 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMs. Lisa Mary Whewell Anson (Age 56)CEO & Executive Director Comp: $608.13kMr. Peter J. CollumChief Financial OfficerDr. James Mead (Age 46)Chief Operating Officer Comp: $132.67kDr. Richard ArmerChief Scientific OfficerDr. Karl Hard Ph.D. (Age 62)Head of Investor Relations Ms. Claire Penelope SolkGeneral Counsel & Company SecretaryMs. Caitlin PearsonHead of CommunicationsDr. Cliff JonesSenior Vice President of Chemistry, DMPK & Intellectual PropertyDr. Caroline PhillipsSenior Vice President of BiologyMr. Craig TilstonHead of Development OperationsMore ExecutivesKey CompetitorsTissue Regenix GroupLON:TRXArecor TherapeuticsLON:ARECPoolbeg PharmaLON:POLBBiodexa PharmaceuticalsLON:MTPHCollagen Solutions plc (COS.L)LON:COSView All CompetitorsInsidersLisa AnsonBought 115,000 shares on 4/16/2024Total: £1.04 M ($9.00/share)Lisa AnsonBought 399,000 shares on 4/11/2024Total: £3.19 M ($8.00/share) REDX Stock Analysis - Frequently Asked Questions How have REDX shares performed in 2024? Redx Pharma's stock was trading at GBX 22 on January 1st, 2024. Since then, REDX shares have decreased by 47.4% and is now trading at GBX 11.57. View the best growth stocks for 2024 here. How were Redx Pharma's earnings last quarter? Redx Pharma Plc (LON:REDX) announced its quarterly earnings results on Monday, November, 19th. The company reported ($7.00) EPS for the quarter, missing analysts' consensus estimates of ($6.50) by $0.50. What other stocks do shareholders of Redx Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Redx Pharma investors own include Digital Globe Services (DGS), OptiBiotix Health (OPTI), TLA Worldwide (TLA), Be Heard Group plc (BHRD.L) (BHRD), Salesforce (CRM), Carnival Co. & (CCL), Burberry Group (BRBY), boohoo group (BOO) and Bank of New York Mellon (BK). How do I buy shares of Redx Pharma? Shares of REDX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:REDX) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden’s $374B Giveaway Into This SectorDTIThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe “Perfect Storm” for GoldGold Safe ExchangeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Redx Pharma Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.